We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ENTA market cap is 187.52M. The company's latest EPS is USD -6.3155 and P/E is -1.41.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 18.89M | 18.93M | 18M | 17.05M | 17.97M |
| Operating Income | -36.71M | -31.03M | -34.89M | -32.77M | -24.19M |
| Net Income | -39.07M | -28.11M | -33.41M | -31.16M | -22.66M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 205.2M | 122.47M | 97.07M | 86.16M | 79.2M |
| Operating Income | 36.74M | -41.64M | -109.57M | -123.84M | -137.21M |
| Net Income | 46.38M | -36.17M | -79M | -121.76M | -133.82M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 495.17M | 462.28M | 428.5M | 413.56M | 398.82M |
| Total Liabilities | 257.35M | 245.54M | 236.62M | 247.44M | 249.91M |
| Total Equity | 237.82M | 216.74M | 191.88M | 166.11M | 148.92M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 489.83M | 486.13M | 438.79M | 375.41M | 462.28M |
| Total Liabilities | 27.34M | 30.55M | 39.36M | 54.08M | 245.54M |
| Total Equity | 462.49M | 455.58M | 399.43M | 321.33M | 216.74M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -81.55M | -103.15M | -24.99M | -53.59M | -68.36M |
| Investing | -65.41M | -53.58M | -13.12M | 45.51M | 39.16M |
| Financing | 198.15M | 198.13M | -7.35M | -13.76M | -20.41M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 71.42M | 7.09M | -70M | -84.78M | -103.15M |
| Investing | -86.66M | 19.83M | 36.99M | 54.9M | -53.58M |
| Financing | 2.57M | 8.98M | 3.08M | 20.03M | 198.13M |
| Market Cap | 187.52M |
| Price to Earnings Ratio | -1.41 |
| Price to Sales Ratio | 2.38 |
| Price to Cash Ratio | 2.2 |
| Price to Book Ratio | 0.87 |
| Dividend Yield | - |
| Shares Outstanding | 21.19M |
| Average Volume (1 week) | 144.32k |
| Average Volume (1 Month) | 113.96k |
| 52 Week Change | -6.55% |
| 52 Week High | 17.80 |
| 52 Week Low | 8.51 |
| Spread (Intraday) | 0.08 (0.9%) |
| Company Name | Enanta Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.enanta.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
